Structure-Guided Design of Pyrazolopyrimidinones as Highly Potent and Selective Allosteric SHP2 Inhibitors
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.5c00524 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Yihui Song und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China. Hauptthemen laut MEDLINE: Protein Tyrosine Phosphatase, Non-Receptor Type 11, Antineoplastic Agents, Pyrimidinones, Pyrazoles. Die Arbeit nennt 48 Literaturangaben. Gefördert von: Natural Science Foundation of Henan Province, Fujian Medical University, Key Scientific Research Project of Colleges and Universities in Henan Province.
Abstract (Originalsprache)
Src homology-2-containing protein tyrosine phosphatase 2 (SHP2) plays crucial roles in various biological processes and has become a promising target for cancer therapy. In this work, we presented the structure-guided design of new allosteric SHP2 inhibitors, leading to the identification of the pyrazolopyrimidinone derivatives TK-684 and TK-685. Both compounds were highly potent and selective allosteric SHP2 inhibitors (TK-684: SHP2WT IC50 = 2.1 nM; Ki = 0.89 nM; TK-685: SHP2WT IC50 = 1.5 nM; Ki = 0.87 nM), likely binding to the "tunnel" allosteric site of SHP2. By targeting SHP2-mediated AKT and ERK signaling pathways, TK-684 and TK-685 suppressed cell proliferation and induced apoptosis in esophageal cancer cells. Additionally, oral administration of TK-685 demonstrated good antitumor effects in the KYSE-150 xenograft mouse model, with a T/C value of 76.8%. Collectively, the pyrazolopyrimidinone derivatives represent promising lead compounds for the treatment of esophageal cancer, where SHP2 is dysregulated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.
- Key Laboratory of Gastrointestinal Cancer (Fujian Medical University), Ministry of Education, Fujian Medical University, Fuzhou 350122, China.
- Tianjian Laboratory of Advanced Biomedical Sciences, Institute of Advanced Biomedical Sciences, Zhengzhou University, Zhengzhou 450001, China.
- State Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, College of Chemistry, Zhengzhou University, Zhengzhou 450001, China.
ORCID-Profile: Bin Yu
Förderung
- Natural Science Foundation of Henan Province
- Fujian Medical University
- Key Scientific Research Project of Colleges and Universities in Henan Province
- National Natural Science Foundation of China
- Chunhui Project Foundation of the Education Department of China
Zitieren
APA
Song, Y., Ren, X., Yang, X., Xiong, J., Wang, W., Tang, K., & Yu, B. (2025). Structure-Guided Design of Pyrazolopyrimidinones as Highly Potent and Selective Allosteric SHP2 Inhibitors. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c00524
Vancouver
Song Y, Ren X, Yang X, Xiong J, Wang W, Tang K, et al. Structure-Guided Design of Pyrazolopyrimidinones as Highly Potent and Selective Allosteric SHP2 Inhibitors. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c00524
BibTeX
@article{Song2025,
author = {Song, Yihui and Ren, Xiangli and Yang, Xinyu and Xiong, Jinbo and Wang, Wenwen and Tang, Kai and Yu, Bin},
title = {Structure-Guided Design of Pyrazolopyrimidinones as Highly Potent and Selective Allosteric SHP2 Inhibitors},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.5c00524}
}
EUVIMED